{
    "ticker": "ARKG",
    "name": "ARK Genomic Revolution ETF",
    "description": "The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that focuses on companies involved in the genomic revolution. Launched by ARK Invest, the fund aims to capitalize on advancements in genomic research and technology that are revolutionizing healthcare, agriculture, and various industries. ARKG invests in companies that are engaged in DNA sequencing, gene editing, and the development of molecular diagnostics, among other areas. The ETF seeks to provide investors with exposure to firms at the forefront of breakthroughs in genomic science, which are expected to drive significant improvements in disease treatment and prevention, as well as innovations in personalized medicine. The fund's investment strategy is rooted in the belief that advancements in genomics will lead to transformative changes in how diseases are treated and managed. ARKG is managed by a team of experts with a deep understanding of the biotechnology space and a commitment to identifying disruptive innovations. The ETF is notable for its active management approach, allowing the team to adjust portfolio holdings based on market conditions and emerging trends in the genomic sector. With a growing focus on biotechnology and genomics in the investment landscape, ARKG offers a unique opportunity for investors looking to gain exposure to this rapidly evolving field.",
    "industry": [
        "Biotechnology",
        "Healthcare"
    ],
    "headquarters": "New York City, New York, USA",
    "founded": "2014",
    "website": "https://ark-funds.com/arkg",
    "ceo": "Cathie Wood",
    "social_media": {
        "twitter": "https://twitter.com/ARKInvest",
        "linkedin": "https://www.linkedin.com/company/ark-invest/"
    },
    "investor_relations": "https://ark-funds.com/arkg",
    "key_executives": [
        {
            "name": "Cathie Wood",
            "position": "CEO"
        },
        {
            "name": "Brett Winton",
            "position": "Director of Research"
        }
    ],
    "product_categories": [
        {
            "category": "Genomic Companies",
            "products": [
                "CRISPR Therapeutics",
                "Illumina",
                "Exact Sciences Corporation"
            ]
        }
    ],
    "seo": {
        "meta_title": "ARK Genomic Revolution ETF (ARKG) | Invest in the Future of Genomics",
        "meta_description": "Explore the ARK Genomic Revolution ETF (ARKG), which invests in companies pioneering innovative genomic technologies and solutions. Learn more about ARKG's investment strategy and holdings.",
        "keywords": [
            "ARKG",
            "Genomics",
            "Biotechnology",
            "Healthcare",
            "Cathie Wood",
            "CRISPR",
            "DNA Sequencing"
        ]
    },
    "faq": [
        {
            "question": "What is ARKG focused on?",
            "answer": "ARKG focuses on companies involved in the genomic revolution, including those in DNA sequencing and gene editing."
        },
        {
            "question": "Who manages ARKG?",
            "answer": "ARKG is managed by ARK Invest, led by CEO Cathie Wood."
        },
        {
            "question": "Where is ARKG headquartered?",
            "answer": "ARKG is headquartered in New York City, New York, USA."
        },
        {
            "question": "What types of companies does ARKG invest in?",
            "answer": "ARKG invests in companies engaged in genomics, biotechnology, and healthcare innovations."
        },
        {
            "question": "When was ARKG founded?",
            "answer": "ARKG was founded in 2014."
        }
    ],
    "competitors": [
        "IBB",
        "XBI",
        "PBE"
    ],
    "related_stocks": [
        "NVTA",
        "TDOC",
        "EDIT",
        "CRSP"
    ]
}